OncoMatch/Clinical Trials/NCT06023862
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Is NCT06023862 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for ovarian neoplasms.
Treatment: Dostarlimab · Bevacizumab · Doxorubicin · Gemcitabine · Paclitaxel · Pegylated liposomal doxorubicin — Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma. 198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio. 1. Group A: Dostarlimab monotherapy * First 3 cycles: Dostalimab 500mg every 3 weeks, IV * 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV 2. Group B: Dostarlimab + Bevacizumab combination therapy * First 3 cycles: Dostalimab 500mg every 3 weeks, IV * 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV * Bevacizumab administered IV at 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity 3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Biomarker criteria
Required: WT1 wild-type (negative)
WT-1 neg (Only in case of ovarian cancer)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Disease progression within 12 months of completing platinum-based chemotherapy
Cannot have received: chemotherapy
Patient has had ≥ 6 prior lines of chemotherapy
Cannot have received: anti-PD-1 therapy
Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-PD-L1 therapy
Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-PD-L2 therapy
Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anticancer therapy
Exception: Palliative radiation therapy to a small field ≥ 1 week prior to Day 1 of study treatment may be allowed after discussion with the SPONSOR.
Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or < 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.
Lab requirements
Blood counts
absolute neutrophil count ≥ 1,500 cells/μl; platelets ≥ 100,000 cells/μl; hemoglobin ≥ 9 g/dl or ≥ 5.6 mmol/l
Kidney function
serum creatinine ≤ 1.5× uln or calculated creatinine clearance ≥ 50 ml/min using the cockcroft-gault equation for patients with creatinine levels > 1.5× institutional uln
Liver function
total bilirubin ≤ 1.5× uln (≤ 2.0 x uln in patients with known gilbert's syndrome) or direct bilirubin ≤ 1× uln; ast and alt ≤ 2.5× uln unless liver metastases are present, in which case they must be ≤ 5× uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06023862 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, anti-PD-1 therapy, anti-PD-L1 therapy disqualifies patients from enrollment.
Does this trial require WT1?
Yes, WT1 wild-type is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages